Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
Justin M. Watts(Sylvester Comprehensive Cancer Center), Pankit Vachhani(University of Alabama at Birmingham), Alessandra Iurlo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Anthony M. Hunter(Emory University), Brandon McMahon(University of Colorado Anschutz Medical Campus), Lea Burke(Incyte (United States)), Emma Searle(University of Manchester), Fred Zheng(Incyte (United States)), Akihiro Tomita(Nagoya University), Srinivas K. Tantravahi(University of Utah), Brandi Reeves(University of North Carolina at Chapel Hill), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Vikas Gupta(Indian Institute of Technology Kanpur), Rosa Ayala(Hospital Universitario 12 De Octubre), María Teresa Gómez‐Casares(Universidad de Las Palmas de Gran Canaria), Anna B. Halpern(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Junichiro Yuda(National Cancer Center Hospital East), Xuejun Chen(Yunnan Academy of Agricultural Sciences), Feng Zhou(Nanchang University), Alessandro Vannuchhi(University of Florence), Francesca Palandri(Istituto Oncologico Romagnolo)
Cited by 5
Related Papers
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
|Blood|2014|429